Compare Divis Laboratories with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs UNICHEM LAB - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES UNICHEM LAB DIVIS LABORATORIES/
UNICHEM LAB
 
P/E (TTM) x 59.8 -40.7 - View Chart
P/BV x 13.8 1.0 1,376.9% View Chart
Dividend Yield % 0.4 1.4 32.1%  

Financials

 DIVIS LABORATORIES   UNICHEM LAB
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
UNICHEM LAB
Mar-19
DIVIS LABORATORIES/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs1,639292 561.4%   
Low Rs1,115182 612.6%   
Sales per share (Unadj.) Rs186.3167.7 111.1%  
Earnings per share (Unadj.) Rs51.0-3.6 -1,403.5%  
Cash flow per share (Unadj.) Rs57.35.9 964.7%  
Dividends per share (Unadj.) Rs16.004.00 400.0%  
Dividend yield (eoy) %1.21.7 68.8%  
Book value per share (Unadj.) Rs261.8372.3 70.3%  
Shares outstanding (eoy) m265.4770.38 377.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x7.41.4 522.9%   
Avg P/E ratio x27.0-65.3 -41.4%  
P/CF ratio (eoy) x24.039.9 60.2%  
Price / Book Value ratio x5.30.6 826.3%  
Dividend payout %31.4-110.2 -28.5%   
Avg Mkt Cap Rs m365,59216,680 2,191.8%   
No. of employees `00011.82.6 455.3%   
Total wages/salary Rs m5,4232,393 226.6%   
Avg. sales/employee Rs Th4,175.14,535.2 92.1%   
Avg. wages/employee Rs Th457.7919.8 49.8%   
Avg. net profit/employee Rs Th1,141.8-98.2 -1,162.7%   
INCOME DATA
Net Sales Rs m49,46311,801 419.2%  
Other income Rs m1,556984 158.1%   
Total revenues Rs m51,01912,785 399.1%   
Gross profit Rs m18,718-835 -2,242.0%  
Depreciation Rs m1,689674 250.7%   
Interest Rs m3575 46.5%   
Profit before tax Rs m18,551-600 -3,093.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,023-343 -1,462.5%   
Profit after tax Rs m13,527-256 -5,293.9%  
Gross profit margin %37.8-7.1 -534.9%  
Effective tax rate %27.157.3 47.3%   
Net profit margin %27.3-2.2 -1,263.0%  
BALANCE SHEET DATA
Current assets Rs m46,50120,384 228.1%   
Current liabilities Rs m8,4685,029 168.4%   
Net working cap to sales %76.9130.1 59.1%  
Current ratio x5.54.1 135.5%  
Inventory Days Days131105 124.9%  
Debtors Days Days86135 63.7%  
Net fixed assets Rs m25,7979,023 285.9%   
Share capital Rs m531141 377.1%   
"Free" reserves Rs m68,96226,058 264.6%   
Net worth Rs m69,49326,199 265.3%   
Long term debt Rs m00-   
Total assets Rs m80,38331,496 255.2%  
Interest coverage x531.0-7.0 -7,613.5%   
Debt to equity ratio x00-  
Sales to assets ratio x0.60.4 164.2%   
Return on assets %16.9-0.6 -2,946.9%  
Return on equity %19.5-1.0 -1,995.8%  
Return on capital %26.7-2.0 -1,337.7%  
Exports to sales %069.4 0.0%   
Imports to sales %24.60-   
Exports (fob) Rs mNA8,188 0.0%   
Imports (cif) Rs m12,187NA-   
Fx inflow Rs m41,2388,188 503.6%   
Fx outflow Rs m12,405596 2,081.4%   
Net fx Rs m28,8337,592 379.8%   
CASH FLOW
From Operations Rs m9,543-3,278 -291.1%  
From Investments Rs m-6,854-2,860 239.6%  
From Financial Activity Rs m-2,459-24 10,162.8%  
Net Cashflow Rs m230-4,690 -4.9%  

Share Holding

Indian Promoters % 52.0 50.1 103.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 15.1 78.1%  
FIIs % 19.0 3.0 633.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 31.7 54.3%  
Shareholders   31,796 20,176 157.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   PROCTER & GAMBLE HEALTH  STERLING BIOTECH  TORRENT PHARMA  VENUS REMEDIES  CIPLA  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Falls Over 750 Points from Day's High; Metal and Realty Stocks Witness Selling(Closing)

After opening the day on a strong note, Indian share markets witnessed a sharp sell-off during closing hours today and ended lower.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (2QFY20); Net Profit Down 10.3% (Quarterly Result Update)

Nov 11, 2019 | Updated on Nov 11, 2019

For the quarter ended September 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 10.3% YoY). Sales on the other hand came in at Rs 14 bn (up 12.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES 2018-19 Annual Report Analysis (Annual Result Update)

Oct 10, 2019 | Updated on Oct 10, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

More Views on News

Most Popular

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jan 21, 2021 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS